EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody–Drug Conjugate HER3

EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody–Drug Conjugate HER3–DXd

Published:2021-09-21 Issue:1 Volume:82 Page:130-141
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Haikala Heidi M.^ORCID,Lopez Timothy^ORCID,Köhler Jens^ORCID,Eser Pinar O.^ORCID,Xu Man,Zeng Qing,Teceno Tyler J.,Ngo Kenneth,Zhao Yutong,Ivanova Elena V.,Bertram Arrien A.^ORCID,Leeper Brittaney A.,Chambers Emily S.^ORCID,Adeni Anika E.,Taus Luke J.^ORCID,Kuraguchi Mari,Kirschmeier Paul T.,Yu Channing^ORCID,Shiose Yoshinobu,Kamai Yasuki,Qiu Yang,Paweletz Cloud P.,Gokhale Prafulla C.,Jänne Pasi A.^ORCID

Funder

American Cancer Society

the National Cancer Institute

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

2. Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA?;Lung Cancer: Targets and Therapy;2024-07

3. Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation;Annals of Oncology;2024-07

4. Molecular Mechanisms and Potential Predictive Biomarkers in Advanced Non-small Cell Lung Cancer: A Summary of Current and Future Trends;Archives of Surgery and Clinical Research;2024-06-27

5. Top advances of the year: Targeted therapy for lung cancer;Cancer;2024-06-21